Get the Stockscreener App
0.285
3.72%
-0.011
After Hours:
.27
-0.015
-5.26%
Oragenics Inc stock is traded at $0.285, with a volume of 7.36M.
It is down -3.72% in the last 24 hours and down -30.49% over the past month.
Oragenics, Inc. focuses on developing antibiotics against infectious diseases and treatments for oral mucositis. It is developing OG716, an antibiotic product candidate, which is in nonclinical testing for healthcare-associated infections, as well as other homolog antibiotic product candidates. The company is also developing AG013, which is in Phase II clinical trial for the treatment of oral mucositis in cancer patients. Its product candidates also comprise LPT3-04, a naturally occurring dietary substance for weight loss; and SMaRT Replacement Therapy, a topical treatment applied to the teeth to protect against tooth decay. Oragenics, Inc. has collaboration agreements with Intrexon Corporation and its subsidiary, Intrexon Actobiotics NV to develop AG013 as a potential treatment of oral mucositis for cancer patients. It also has license agreements with LPThera LLC to develop LPT3-04, a weight-loss product candidate; and Texas A&M University System for access to new homologs of the lantibiotic Mutacin 1140 (MU1140) and other lantibiotics, as well as holds licenses from the University of Florida Research Foundation, Inc. for MU1140 product candidates. The company was formerly known as Oragen, Inc. Oragenics, Inc. was founded in 1996 and is headquartered in Tampa, Florida.
See More
Previous Close:
$0.296
Open:
$0.2782
24h Volume:
7.36M
Relative Volume:
1.55
Market Cap:
$3.91M
Revenue:
-
Net Income/Loss:
$-20.26M
P/E Ratio:
-0.0334
EPS:
-8.54
Net Cash Flow:
$-8.25M
1W Performance:
-7.05%
1M Performance:
-30.49%
6M Performance:
-69.15%
1Y Performance:
-88.37%
1-Day Range:
$0.25
$0.2875
1-Week Range:
$0.25
$0.6299
52-Week Range:
$0.25
$4.00
Oragenics Inc Stock (OGEN) Company Profile
Name
Oragenics Inc
Sector
Industry
Phone
813-286-7900
Address
4902 Eisenhower Boulevard, Suite 125, Tampa, FL
Compare OGEN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OGEN
Oragenics Inc
|
0.285 | 3.91M | 0 | -20.26M | -8.25M | -8.54 |
|
VRTX
Vertex Pharmaceuticals Inc
|
481.16 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.07 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
657.97 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
278.25 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
119.94 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Oragenics Inc Stock (OGEN) Latest News
There is no way Arrowhead Pharmaceuticals Inc (ARWR) can keep these numbers up - SETE News
Views of Wall Street’s Leading Experts on Oragenics Inc - SETE News
Oragenics, Inc. Chief Medical Officer, Dr. James P. Kelly, - GlobeNewswire
Power Nickel’s (TSX.V: PNPN) Hole Delivers “BIG”- Gold Terra (TSX.V: YGT) Developments and Exploration Progress Reported – More Stocks Inside! | FinancialContent Business Page - Financial Content
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
OGEN’s valuation metrics: A comprehensive analysis - US Post News
In the Green: Oragenics Inc (OGEN) Closes at 0.28, Up/Down -2.34 from Previous Day - The Dwinnex
Closing Bell Recap: Merck & Co Inc (MRK) Ends at 90.74, Reflecting a -9.07 Downturn - The Dwinnex
Market Insights: 4D Molecular Therapeutics Inc (FDMT)’s Notable Drop of -0.17, Closing at 5.92 - The Dwinnex
Post-Trade Analysis: Charter Communications Inc (CHTR) Slides -0.36, Closing at 340.26 - The Dwinnex
US Stocks Mixed; Walt Disney Posts Upbeat Earnings - Benzinga India
United Micro Electronics ADR [UMC] Investment Guide: What You Need to Know - Knox Daily
Oragenics Inc (OGEN) may enjoy gains as insiders got busy in the recent days - Knox Daily
The Potential Rise in the Price of Dolby Laboratories Inc (DLB) following insiders activity - Knox Daily
Oragenics Inc Inc. (OGEN) Price Performance: A Fundamental Analysis Perspective - The InvestChronicle
PCSO Lotto Results | February 5, 2025 - The Manila Times
Citigroup lifts StoneCo Ltd [STNE] price estimate. Who else is bullish? - The DBT News
Oragenics (NYSE:OGEN) Coverage Initiated at StockNews.com - Defense World
Rubicon Technology (NASDAQ:RBCN) Now Covered by StockNews.com - Defense World
BlackRock Long-Term Municipal Advantage Trust (NYSE:BTA) Enters Standstill Agreement with Saba Capital Management, L.P.On January 20, 2025, BlackRock Long-Term Municipal Advantage Trust (NYSE:BTA) disclosed that it, along with BlackRock Advis - Defense World
Credit Suisse Group (NYSE:CS) Now Covered by StockNews.com - Defense World
Dermata Therapeutics Signs Clinical Trial Collaboration Agreement with Revance Therapeutics for Topical Treatment StudyDermata Therapeutics, Inc. (NASDAQ: DRMA) revealed in an 8-K filing that on January 17, 2025, the company entered into a Clinical T - Defense World
Oragenics, Inc. Update: Janet Huffman Appointed Interim CEO - Defense World
Oragenics (OGEN) Stock Price, News & Analysis - MarketBeat
Oragenics gears up for Phase II trials, appoints new CEO By Investing.com - Investing.com Australia
Oragenics, Inc. Provides Shareholder Update on Strategic Progress and Announces Janet Huffman as Interim CEO - GlobeNewswire
Oragenics gears up for Phase II trials, appoints new CEO - MSN
Ocean Power Technologies Demonstrates Multi-Day Advanced Remote Survey Capabilities - The Manila Times
Oragenics appoints interim CEO, ups CFO salary By Investing.com - Investing.com Canada
Oragenics appoints interim CEO, ups CFO salary - MSN
Oragenics Announces Leadership Changes and Relocation - TipRanks
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
Why Energy Transfer Rocketed 42% in 2024 - The Globe and Mail
Pre-market Movers: AVGR, TIVC, ATNF, SLGL... - RTTNews
XOMA (NASDAQ:XOMA) and Oragenics (NYSE:OGEN) Head to Head Review - Defense World
Cencora Expands Specialty Leadership with $4.4 Billion Acquisition of Retina Consultants of America - MSN
Oragenics (NYSE:OGEN) Now Covered by StockNews.com - Defense World
Anti-Oral Mucositis Drug Market 2025-2032: Revenue Growth, Business Opportunities, Trends and Forecast - WICZ
Oragenics (NYSE:OGEN) Now Covered by Analysts at StockNews.com - Defense World
Oragenics Simplifies Capital Structure and Advances Strategy - TipRanks
Oragenics, Inc. Announces Conversion of Preferred Shares and Elimination of Liquidation Preference - The Manila Times
Oragenics Strengthens Balance Sheet: $2.35M Preferred Share Conversion Streamlines Capital Structure - StockTitan
Oragenics director Alan Dunton sells $23 in common stock By Investing.com - Investing.com Canada
Oragenics director Alan Dunton sells $23 in common stock - Investing.com
Oragenics director Fred Telling sells $1,294 in common stock - Investing.com
Oragenics director Fred Telling sells $1,294 in common stock By Investing.com - Investing.com UK
Certain Preferred Stock of Oragenics, Inc. are subject to a Lock-Up Agreement Ending on 5-DEC-2024. - Marketscreener.com
Certain Warrants of Oragenics, Inc. are subject to a Lock-Up Agreement Ending on 5-DEC-2024. - Marketscreener.com
Oragenics announces termination of president's employment agreement By Investing.com - Investing.com South Africa
Oragenics announces termination of president's employment agreement - Investing.com India
Oragenics Inc Stock (OGEN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.82%
0.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):